Browsing Tag
Acute myeloid leukemia
35 posts
Can Japanese patent leverage strengthen Annamycin’s hand in AML?
Moleculin Biotech secures Japanese patent for Annamycin. Explore how this IP move could shape AML strategy and global commercialization plans.
AVEO Oncology begins Phase 1b/2 ficlatuzumab trial in elderly AML patients via Blood Cancer United collaboration
AVEO Oncology has begun a Beat AML trial for ficlatuzumab in elderly AML patients. See how this could reshape front-line cancer care for high-risk groups.
Amgen (NASDAQ: AMGN) bets on protein degradation with Dark Blue Therapeutics acquisition
Amgen acquires Dark Blue Therapeutics for up to $840M, expanding into MLLT1/3-targeted AML therapies. Find out what this means for oncology innovation today.
Moleculin hits key inflection point as pivotal MIRACLE Phase 3 AML trial completes treatment for first 45 patients
Find out how Moleculin Biotech’s pivotal MIRACLE Phase 3 milestone for Annamycin could reshape treatment for relapsed AML as Q1 2026 data approaches.
Cullinan Therapeutics showcases early AML response with CLN-049 T-cell engager at ASH 2025
Discover how Cullinan Therapeutics’ CLN-049 showed early AML responses at ASH 2025 and what it could mean for future leukemia treatment and investors.
Hanmi Pharmaceutical to acquire Aptose Biosciences in C$2.41-per-share deal with 28% premium
Find out how Hanmi Pharmaceutical’s acquisition of Aptose Biosciences is reshaping the AML treatment landscape today!
Can Moleculin’s MIRACLE trial redefine AML treatment? Company to showcase study at leukemia event
Find out how Moleculin’s MIRACLE phase 3 trial could reshape AML treatment as the company presents its latest progress at the Madrid leukemia meeting.
How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients
Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike.
CERo Therapeutics moves forward in Phase 1 AML study as CER-1236 passes first-dose safety review
CERo Therapeutics completes first cohort of its Phase 1 AML trial with no dose-limiting toxicities—discover how CER-1236 could reshape immunotherapy.
Hemogenyx Pharmaceuticals stock jumps after third patient in CAR-T AML trial shows safety and early efficacy
Hemogenyx Pharmaceuticals (LSE: HEMO) stock jumps 24% after third patient treated in CAR-T AML trial shows safety and early efficacy.